The Managing Director, MD, of Ferring Pharmaceuticals, Pascal Danglas has been apointed the company’s Executive Vice President and Chief Medical Officer.
Per Falk, MD, PhD has also been appointed Executive Vice President and Chief Scientific Officer. Both appointments are effective as of February 1st.

According to Ferring, it aims to expand its portfolio and improve patient access to our products.

Michel Pettigrew, President of the Executive Board and Chief Operating Officer of Ferring indicated that focusing on the company’s efforts in R&D and patient access under these two proven leaders, Ferring is positioning itself is to accelerate growth and better meet patient needs.

As Chief Medical Officer, Pascal Danglas will evaluate and advise on new product candidates. He will also focus on strengthening patient access to Ferring products as the company?s liaison to the medical community, patients and national reimbursement authorities. An industry veteran, Danglas previously served as executive vice president of clinical and product development with Ferring.

Per Falk joins Ferring as Chief Scientific Officer after a successful assignment as senior vice president responsible for biopharmaceuticals research at Novo Nordisk A/S. In his new role, Falk will be responsible for overseeing the entirety of Ferring?s research and development activities, from basic research through to regulatory approval.



Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.